Monitor for the filing of a Form D and a Form 8-K with the SEC, which will confirm the closing of the offering and provide details on the final amount raised. The stock is currently illiquid and trades on the OTC market, so any impact on the share price will depend on market perception of the capital raise and the company's ability to execute on its growth initiatives.
Price Chart
Executive Summary
Palomino Laboratories Inc. (PALX) is conducting a private placement offering of up to 7.5 million shares at $4.00 per share, raising up to $30 million. The funds will be used for general corporate and working capital purposes. The offering is being conducted on a 'best efforts' basis to accredited investors, with Laidlaw & Company (UK) Ltd. serving as the exclusive placement agent.
Key Financial Metrics
Key Facts
- Palomino Laboratories Inc. is offering up to 7,500,000 shares of common stock at $4.00 per share, for a maximum offering size of $30,000,000.
- The offering has a minimum threshold of 3,750,000 shares ($15,000,000) and will close in one or more closings by March 31, 2026 (extendable to April 30, 2026).
- The shares are being sold in a private placement to accredited investors under exemptions from registration (Section 4(a)(2) and Rule 506(b) of Regulation D).
- Laidlaw & Company (UK) Ltd. is the exclusive placement agent and will receive a 10% cash fee on proceeds, a 2% expense allowance, and warrants to purchase 10% of the shares sold (excluding shares sold to company-introduced parties).
- Proceeds from the offering will be used for general corporate and working capital purposes, including operations and growth initiatives.
Financial Impact
The company will raise up to $30 million in gross proceeds from the sale of up to 7.5 million shares at $4.00 per share. After placement agent fees and expenses, net proceeds will be used for general corporate purposes.
Risk Factors
- The offering is being conducted on a 'best efforts' basis, meaning there is no guarantee that the company will raise the full $30 million or even meet the $15 million minimum.
- The company is a former shell company, and Rule 144 restrictions prevent resale of the shares for one year after the company files Form 10 information, creating significant liquidity risk for investors.
- There are potential conflicts of interest, as key individuals at the placement agent also have affiliations with Lucius Partners, a significant shareholder of the company.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-018963 |
| Exhibit: ex10-1.htm | 0001493152-26-018963 |
| Exhibit: ex10-2.htm | 0001493152-26-018963 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K/A | $14.32 | awaiting T+60 | — | $14.01 (−2.16%) |
Oct 8, 2026 18d ago | DEF 14A | $16.00 | awaiting T+60 | — | $14.01 (−12.44%) |
Jul 16, 2026 14w ago | 8-K | $7.35 $14.01 | ▲ +90.61% | ▲ +86.64% | $14.01 (+90.61%) |
May 5, 2026 24w ago | 8-K | — | awaiting T+60 | — | — |
Apr 24, 2026 26w ago | 8-K | — | awaiting T+60 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers